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INTRODUCTION
Beh et’ s disease (BD) is a multisystemic disorder charac-
terized by oral ulcerations, genital ulcerations, uveitis, and
skin lesions, most likely occurring due to underlying vasculi-
tis. There are also other organ involvements, including joints,
heart, lungs, neurological involvement, and gastrointestinal
involvement. Because the pathognomonic diagnostic tools
are lacking, the diagnosis mainly depends upon the thorough
history taking and clinical features. Pathergy reaction (PR),
a nonspecific hypersensitivity of the skin to a needleprick, has
been known to be a curious and unique phenomenon occur-
ring in patients with BD, and proposed as a useful adjunct to
diagnosis. This phenomenon has been accepted as one among
the major criteria of International Study Group (ISG) (1).
The prevalence of a positive PR varies according to coun-
tries or investigators. The high positive rate of PR has been
described in some ethnic areas such as Turkey (2, 3), Iran (4),
Japan (5), and Israel (6), but this was not the case in other
countries (7, 8). After the introduction of a disposable nee-
dle, the prevalence and intensity of a positive PR in BD pa-
tients has been described to decrease, when compared to non-
disposable needle used in pre-AIDS era (9). On the other
hand, there have been conflicting results between the PR
and the clinical features of BD. Information about the rela-
tionship between PR and the disease activity is limited. In
addition, some investigators (10) and we noticed that a few
patients with BD with a negative PR developed a pustule
formation at the venous puncture site (PFVPS) for the intra-
venous fluid infusion or blood draw.
Therefore, this study was undertaken to evaluate the fre-
quency of a positive PR, the intensity and disease specificity
of this reaction in patients with BD when a disposable nee-
dle is used, to clarify the clinical association between the PR
and the clinical features of BD or its disease activity, and to
assess whether the patients with PFVPS without a positive
PR could be regarded as a positive reaction.
MATERIALS AND METHODS
The study subjects included 64 patients with BD (25 males
and 39 females) who fulfilled the ISG criteria, 74 patients
without BD (24 males and 50 females) consisting of 24 pa-
tients with recurrent aphthous stomatitis, 19 patients with
systemic lupus erythematosus (SLE), 13 patients with Sjogren
syndrome, 15 patients with spondyloarthropathy (SpA) and
3 patients with ulcerative colitis, along with 20 age and sex-
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Behcet’ s Disease
This study was done to evaluate the frequency, intensity, and specificity of a posi-
tive pathergy reaction (PR) in Behcet’s disease (BD) patients, to clarify an asso-
ciation between the PR and the clinical features or disease severity, and to assess
whether patients with pustule formation at the venous puncture site (PFVPS) with-
out positive PR could be regarded as a positive reaction. The PR was tested in
64 BD patients, 74 disease controls, and 20 healthy controls. Venous PR was
performed in 8 BD patients with PFVPS. Follow-up PR was done in 14 patients
with positive reaction during inactive phase. The PR was positive in 35.9% of BD
patients, in 1 patient among disease controls, and in none of healthy controls. The
pustule formation was observed in one BD patient. There was no statistical sig-
nificance between positive PR and the clinical variables. The mean clinical activ-
ity score of BD patients with positive PR was similar to patients with negative reac-
tion. Venous PR was positive in 7 patients. The follow-up PR was positive in 2
patients during inactive phase. Conclusively the positive PR appeared to be spe-
cific for BD, and was not associated with the clinical variables or disease severi-
ty, but was usually found during active phase in cases with positive reaction.
The PFVPS in patients with negative PR might be considered to be positive.
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matched healthy controls (7 males and 13 females) consist-
ing of hospital personnel. The other demographic features of
BD patients were as follows: mean age at presentation 40.2
±10.3 yr, mean age at onset 35.8±9.5 yr, and mean period
of follow-up 14.6±8.4 months. The mean ages of patients
without BD and healthy controls were 40.6±12.8 yr and
39.5±10.6 yr, respectively. The age at onset was defined at
the time the patient historically fulfilled the ISG criteria. Pa-
tients who were under 29 yr were considered as having the
early disease and those over 30 yr as the late disease.
For the PR, the skin on the flexor aspect of the forearm was
cleaned with 70% isopropyl alcohol and pricked intradermally
with a disposable 21-gauze needle. The results were read at
48 hr by the same physician, and were graded as follows: grade
0, needle mark or erythema only; grade 1, papule; and grade
2, pustule. A grade over 1 was considered as a positive reac-
tion (2, 11). The PR was retested in a few BD patients with
initially negative PR whose disease flared up during the fol-
low-up period. If these results were positive, they were also
considered to have a positive reaction.
Venous PR was performed in 8 patients with BD having a
PFVPS, and in 10 patients without BD (5 patients with SLE,
3 patients with SpA, and 2 patients with Sjogren syndrome)
after obtaining informed consents. Five percent dextrose (500
mL) was infused using a disposable 21-gauze needle for 3 hr
at the forearm. The results were also evaluated at 48 hr. Only
the pustule formation was regarded as a positive venous PR.
Follow-up PR was done in 11 patients with a positive PR,
and follow-up venous PR was done in 3 patients with a pos-
itive venous PR, during the relatively quiescent phase of their
disease.
The clinical activity score (Table 1) was calculated by sum-
ming each clinical manifestation present when a PR was per-
formed. This score was established with reference to the study
of Yazici et al. (3) and in view of the morbidity and the disease
severity of the BD (12).
For statistical analysis, Student t-test and Fisher’ s exact test
were used.
RESULTS
The clinical characteristics of patients with BD are pre-
sented in Table 2. A positive PR was observed in 23 out of
64 BD patients with a positive rate of 35.9%. However, this
reaction was positive in only one patient with SLE among
74 patients without BD, and none had a positive reaction in
healthy controls. In addition, a grade 2 reaction with a pus-
tule formation was only found in one patient with BD. The
PR in patients with BD was not associated with age at onset
of the disease, sex, the clinical features, and the presence of
HLA-B51 (Table 3 and 4). The mean clinical activity score of
BD patients with a positive PR was 2.91±1.31, and that of
BD patients with a negative PR was 2.85±1.17 (p=0.853).
Venous PR was positive in 7 among 8 BD patients with a
PFVPS, and the PR was positive only in 3 among these 8
patients. However, venous PR was negative in all ten patients
without BD.
1 Oral ulceration
Genital ulceration
Skin lesions: EN-like lesions, pseudofolliculitis/PPL
Monoarticular arthritis
Superficial thrombophlebitis
2 Arthritis involving two joints or more
Gastrointestinal ulceration without complications
Small or medium-sized vessel involvement not related to vital 
organ
3 Uveitis
Gastrointestinal ulceration with bleeding or perforation
Major vessel involvement
Major organ involvement such as brain, lungs, or heart
EN: erythema nodosum, PPL: papulopustular lesion.
Table 1. The clinical activity score for Beh et’ s disease
Early disease 24 37.5 
Late disease 40 62.5 
Erythema nodosum 32 50.0 
PPL/pseudofolliculitis 38 59.4 
Gastrointestinal involvement 10 15.6 
Genital ulcer 48 75.0 
Arthritis 18 28.1 
Uveitis 14 21.9 
Positive HLA-B51 33 51.6
No. of patients Percent
Table 2. The clinical characteristics of patients with BD
Early disease 7 (30.4%) 17 (41.5%)
Late disease 16 (69.6%) 24 (58.5%) 0.431
Male  12 (52.2%) 13 (31.7%)
Female 11 (47.8%) 28 (68.3%) 0.120 
Pathergy positive
(n=23)
Pathergy negative
(n=41) p-value
Table 3. The relationship of disease onset of age or sex and a
pathergy reaction in patients with Beh et’ s disease
Erythema nodosum 11 (47.8%) 21 (51.2%) 1.0 
PPL/pseudofolliculitis 15 (65.2%) 23 (56.1%) 0.598 
Genital ulcer 14 (60.9%) 34 (82.9%) 0.072 
Uveitis 3 (13.0%) 11 (26.8%) 0.345 
Gastrointestinal 5 (21.7%) 5 (12.2%) 0.474 
involvement
Arthritis 9 (39.1%) 9 (22.0%) 0.160 
HLA-B51 12 (52.2%) 21 (51.2%) 1.0 
Pathergy 
positive (n=23)
Pathergy 
negative (n=41) p-value
Table 4. The relationship of clinical features and a pathergy
reaction in patients with Beh et’ s disease
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Among 11 patients on the follow-up PR, 2 patients had a
positive reaction during inactive phase of the disease, and 1
patient having a pustule formation in initial PR was observed
a papule without the pustule formation. The follow-up results
of all 3 patients with a positive venous PR were negative dur-
ing inactive phase of the disease (Table 5).
DISCUSSION
Since the PR, which was first described in 1937 by Blobner
(13), has been proven to be helpful for the diagnosis of BD, it
has become one of the ISG criteria. However, after the intro-
duction of the disposable needle, which is less traumatic than
the non-disposable needle, the prevalence and intensity of
positive PR has been known to decrease. This study also recon-
firmed the specificity of the PR in Korean BD, revealing the
positive rate of 35.9% and specificity of 98.9%. The formal
reports on the prevalence of the PR performed in the pre-AIDS
era in Korea have been rare, and one study in 1984 showed a
positive rate of 47.3% (14). In addition, contrary to a Turkish
study on the PR done in the pre-AIDS era that described a
pustule formation in 58% of patients with BD (15), our study
showed that the pustule formation was observed only in one
among 23 patients with a positive reaction. This may be due
to the use of a disposable needle or the ethnic difference.
There have been no controlled studies to determine whether
medications can exert an influence on the results of PR. Some
authors suggested that medications might affect the results
of PR (16), while others might not (17). In the current study,
the PR was done in most cases before initiation of any treat-
ment, or at least one week after discontinuation of treatment.
However, in a few inevitable cases due to the clinical status,
the test was performed with minimum medications. So, we
could not reveal an impact of medications on the results of
the PR.
Up to date, conflicting studies have been reported on the
association between the PR and the clinical features of BD.
Some investigators found that the presence of a positive reac-
tion was not related to the clinical manifestations of the dis-
ease (8, 17). However, the PR was reported to be significantly
associated with vascular involvement (18). Yazici et al. described
that male patients had a stronger PR (19). In addition, it is
plausible that this phenomenon might be associated with the
presence of HLA-B51 in BD, because most patients in a Turk-
ish study simultaneously had HLA-B51 and a positive reac-
tion (20). In our study the PR was not associated with age at
onset of the disease, sex, other clinical features, and the pres-
ence of HLA-B51. However, we could not assess the clinical
association between the PR and the vascular involvement due
to the small number of patients with vascular involvement in
our study group.
It remains unclear whether the presence of a PR reflects the
disease severity. Yurdakul et al. described that the PR was less
commonly positive in patients with milder BD such as those
in the community than in hospital-based patients (21). How-
ever, other investigators claimed that the PR was not associated
with the disease severity (17, 19). On the other hand, although
the rate of a positive reaction could be influenced by the dis-
ease activity when the test has been performed (6, 16), formal
studies have been limited. In the current study, it appeared
that the PR was not related to the disease severity, but was
usually encountered during the active phase of the disease in
individual case with a positive reaction.
Since the sensitivity of the PR has decreased with the intro-
duction of the disposable needle, it was noticed that the
PFVPS had been found in some BD patients with a negative
PR. Even though the standardized method of a PR has been
lacking at present, these patients group have not been consid-
ered to be a positive reaction according to the ISG criteria (22).
The current study suggests that it may be a positive PR, espe-
cially in patients having the clinical features of BD until a more
sensitive and standardized tool for PR becomes available.
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